Novartis: psoriasis drug shows efficacy in Phase III trial
(CercleFinance.com) - Novartis said on Monday that data from a late-stage trial testing its psoriasis drug Cosentyx showed effectiveness amongst Chinese patients.
The Swiss drugmaker today announced new data in 441 Chinese patients with moderate-to-severe plaque psoriasis from a Phase III study investigating the efficacy and safety of the drug.
The data showed that 97.7% of patients treated with Cosentyx achieved improvement in psoriasis as measured by the Psoriasis Area Severity Index (PASI 75) at week 12.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
The Swiss drugmaker today announced new data in 441 Chinese patients with moderate-to-severe plaque psoriasis from a Phase III study investigating the efficacy and safety of the drug.
The data showed that 97.7% of patients treated with Cosentyx achieved improvement in psoriasis as measured by the Psoriasis Area Severity Index (PASI 75) at week 12.
Copyright (c) 2019 CercleFinance.com. All rights reserved.